While p53 mutations are found in over half of NSCLC [158, 159] and over 75% of SCLC [133, 134], the impact of p53 mutations on prognosis remains controversial and can vary between lung cancer subtypes and tumour stage. This evidence concerns the gene TP53 and non-small cell lung carcinoma.